The independent consensus panel of nine leading experts from around the world agreed that:
"FUZEON is an important treatment for the increasing number of patients with HIV drug resistance. By providing clear advice on timing of FUZEON initiation and patient support during therapy, these guidelines clarify the place of this breakthrough drug in current HIV treatment regimens and will enable more pre-treated patients to benefit," stated Dr Mike Youle, Royal Free Hospital, London.
Mr Colin Webb, Executive Director of European Coalition of Positive People (ECPP) commented, "The ECPP welcomes these international consensus guidelines for FUZEON. They are important as they encourage further dialogue between physicians and their patients, ensuring that informed decisions are made on when to consider and successfully introduce FUZEON."
For more information, please contact:
Amanda Boswell
T: 44-207-611-3571
amanda.boswell@ketchum.com
Peter Dixon
T: 44-207-611-3634
peter.dixon@ketchum.com
AIDS